Noninvasive Evaluation of F-FDG/F-FMISO-based Micro PET in Monitoring Hepatic Metastasis of Colorectal Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2018 Dec 15

PMID 30546057

Citations 4

Authors

Mingyu Zhang

Huijie Jiang

Rongjun Zhang

Hailong Xu

Hao Jiang

Wenbin Pan

Xin Li

Yiqiao Wang

Song Wang

Affiliations

Soon will be listed here.

Abstract

This study aimed to explore the application of two radiotracers (F-fluorodeoxyglucose (FDG) and F-fluoromisonidazole (FMISO)) in monitoring hepatic metastases of human colorectal cancer (CRC). Mouse models of CRC hepatic metastases were established by implantation of the human CRC cell lines LoVo and HT29 by intrasplenic injection. Wound healing and Transwell assays were performed to examine cell migration and invasion abilities. Radiotracer-based cellular uptake in vitro and micro-positron emission tomography imaging of liver metastases in vivo were performed. The incidence of liver metastases in LoVo-xenografted mice was significantly higher than that in HT29-xenografted ones. The SUVmax/mean values of F-FMISO, but not F-FDG, in LoVo xenografts were significantly greater than in HT29 xenografts. In vitro, LoVo cells exhibited stronger metastatic potential and higher radiotracer uptake than HT29 cells. Mechanistically, the expression of HIF-1α and GLUT-1 in LoVo cells and LoVo tumor tissues was remarkably higher than in HT29 cells and tissues. Linear regression analysis demonstrated correlations between cellular F-FDG/F-FMISO uptake and HIF-1α/GLUT-1 expression in vitro, as well as between F-FMISO SUVmax and GLUT-1 expression in vivo. F-FMISO uptake may serve as a potential biomarker for the detection of liver metastases in CRC, whereas its clinical use warrants validation.

Citing Articles

Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2.

Jiang H, Guo W, Huang K, Jiang H, Zhang R, Hu H Abdom Radiol (NY). 2021; 46(7):3227-3237.

PMID: 33712897 PMC: 8215036. DOI: 10.1007/s00261-021-03015-w.

Transfer of metastatic traits via miR-200c in extracellular vesicles derived from colorectal cancer stem cells is inhibited by atractylenolide I.

Tang D, Xu X, Ying J, Xie T, Cao G Clin Transl Med. 2020; 10(4):e139.

PMID: 32898324 PMC: 7423185. DOI: 10.1002/ctm2.139.

The critical role of glucose deprivation in epithelial-mesenchymal transition in hepatocellular carcinoma under hypoxia.

Jo H, Lee J, Jeon J, Kim S, Chung J, Ko H Sci Rep. 2020; 10(1):1538.

PMID: 32001727 PMC: 6992695. DOI: 10.1038/s41598-020-58124-1.

Associations between GLUT expression and SUV values derived from FDG-PET in different tumors-A systematic review and meta analysis.

Meyer H, Wienke A, Surov A PLoS One. 2019; 14(6):e0217781.

PMID: 31206524 PMC: 6576787. DOI: 10.1371/journal.pone.0217781.

References

Ruers T, Langenhoff B, Neeleman N, Jager G, Strijk S, Wobbes T . Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002; 20(2):388-95. DOI: 10.1200/JCO.2002.20.2.388. View

Winnard Jr P, Pathak A, Dhara S, Cho S, Raman V, Pomper M . Molecular imaging of metastatic potential. J Nucl Med. 2008; 49 Suppl 2:96S-112S. PMC: 5516907. DOI: 10.2967/jnumed.107.045948. View

Sato J, Kitagawa Y, Yamazaki Y, Hata H, Okamoto S, Shiga T . 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma. J Nucl Med. 2013; 54(7):1060-5. DOI: 10.2967/jnumed.112.114355. View

Norikane T, Yamamoto Y, Maeda Y, Kudomi N, Matsunaga T, Haba R . Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET. Nucl Med Commun. 2013; 35(1):30-5. DOI: 10.1097/MNM.0000000000000010. View

Kawai N, Lin W, Cao W, Ogawa D, Miyake K, Haba R . Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging. 2014; 41(10):1870-8. DOI: 10.1007/s00259-014-2776-9. View

Zheng Z, Zheng R, Zhang S, Chen W . Colorectal cancer incidence and mortality in China, 2010. Asian Pac J Cancer Prev. 2014; 15(19):8455-60. DOI: 10.7314/apjcp.2014.15.19.8455. View

Bourdier T, Greguric I, Roselt P, Jackson T, Faragalla J, Katsifis A . Fully automated one-pot radiosynthesis of O-(2-[18F]fluoroethyl)-L-tyrosine on the TracerLab FX(FN) module. Nucl Med Biol. 2011; 38(5):645-51. DOI: 10.1016/j.nucmedbio.2011.01.001. View

Liang C, Park A, Guan J . In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007; 2(2):329-33. DOI: 10.1038/nprot.2007.30. View

Lam V, Laurence J, Pang T, Johnston E, Hollands M, Pleass H . A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. HPB (Oxford). 2013; 16(2):101-8. PMC: 3921004. DOI: 10.1111/hpb.12083. View

10.

Cheng J, Lei L, Xu J, Sun Y, Zhang Y, Wang X . 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. J Nucl Med. 2013; 54(3):333-40. DOI: 10.2967/jnumed.112.111963. View

11.

Everitt S, Ball D, Hicks R, Callahan J, Plumridge N, Collins M . Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer. J Nucl Med. 2014; 55(7):1069-74. DOI: 10.2967/jnumed.113.131631. View

12.

Edwards B, Ward E, Kohler B, Eheman C, Zauber A, Anderson R . Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2009; 116(3):544-73. PMC: 3619726. DOI: 10.1002/cncr.24760. View

13.

McMillan D, McArdle C . Epidemiology of colorectal liver metastases. Surg Oncol. 2007; 16(1):3-5. DOI: 10.1016/j.suronc.2007.04.008. View

14.

Bosetti C, Levi F, Rosato V, Bertuccio P, Lucchini F, Negri E . Recent trends in colorectal cancer mortality in Europe. Int J Cancer. 2010; 129(1):180-91. DOI: 10.1002/ijc.25653. View

15.

Whisenant J, Peterson T, Fluckiger J, Tantawy M, Ayers G, Yankeelov T . Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer. Mol Imaging Biol. 2012; 15(1):87-96. PMC: 3752931. DOI: 10.1007/s11307-012-0564-0. View

16.

Ding Z, Yang L, Xie X, Xie F, Pan F, Li J . Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J Cancer Res Clin Oncol. 2010; 136(11):1697-707. PMC: 2944968. DOI: 10.1007/s00432-010-0828-5. View

17.

Marcus C, Marashdeh W, Ahn S, Taghipour M, Subramaniam R . ¹⁸F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. J Nucl Med. 2015; 56(7):989-94. DOI: 10.2967/jnumed.115.156240. View

18.

Arvold N, Heidari P, Kunawudhi A, Sequist L, Mahmood U . Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET. Technol Cancer Res Treat. 2015; 15(2):234-42. PMC: 4565779. DOI: 10.1177/1533034615574386. View

19.

Shady W, Kishore S, Gavane S, Do R, Osborne J, Ulaner G . Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0. Eur J Radiol. 2016; 85(6):1224-31. PMC: 5675072. DOI: 10.1016/j.ejrad.2016.03.029. View

20.

Wang H, Zhang J, Tian J, Qu B, Li T, Chen Y . Using dual-tracer PET to predict the biologic behavior of human colorectal cancer. J Nucl Med. 2009; 50(11):1857-64. DOI: 10.2967/jnumed.109.064238. View